Gunderson Dettmer represented Foresite Capital in the formation of the fund’s fifth fund, which is comprised of two separate investment vehicles, Foresite Capital Fund V and Foresite Capital Opportunity Fund V. The firm secured $969 million in capital commitments and will focus on healthcare and life sciences.  

Foresite’s affiliated incubator, Foresite Labs, combined with Foresite’s expertise in public market investing, uniquely positions Foresite to support companies from inception through an IPO and beyond.  In the announcement of the transaction, CEO and founder of Foresite Dr. Jim Tananbaum said, “We can also come into a later situation that’s competitive with a number of hedge funds, and bring something unique to the table, because we have all these value-added resources that we used to start companies. So we have a competitive advantage for later-stage deals, and we have a competitive advantage for early-stage deals, by virtue of being able to function at a high level in the capital markets.”

The Gunderson deal team was led by Christi Niehans Frentz and included Christopher Partin and Sally Yi.